WuXi Biologics (Cayman) (HKG:2269) recorded a 56% rise in attributable profit in the first half of 2025 to 2.34 billion yuan from 1.5 billion yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.

Earnings per share were 0.55 yuan in the half year, up from 0.35 yuan in the corresponding period of the last year.

The vaccine maker's revenue rose 16% to 9.95 billion yuan in the interim period from 8.57 billion yuan a year prior.

The higher revenue was due to a wider spectrum of services offered to the biologics industry, a higher research services revenue, and the utilization of existing and newly expanded capacities among other factors.